Protagonist Therapeutics (NASDAQ:PTGX) Director Sells $1,673,600.00 in Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William Waddill sold 20,000 shares of the company’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the completion of the transaction, the director owned 7,825 shares of the company’s stock, valued at $654,796. This trade represents a 71.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Protagonist Therapeutics Stock Up 4.7%

Shares of PTGX stock opened at $84.49 on Monday. The business has a 50-day moving average price of $85.65 and a two-hundred day moving average price of $73.94. Protagonist Therapeutics, Inc. has a 12-month low of $33.70 and a 12-month high of $96.54. The firm has a market cap of $5.28 billion, a P/E ratio of 136.28 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The firm had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. As a group, research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PTGX has been the topic of several recent research reports. Citizens Jmp increased their target price on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Johnson Rice set a $112.00 price target on shares of Protagonist Therapeutics in a research report on Monday, October 13th. Barclays raised their price objective on Protagonist Therapeutics from $88.00 to $108.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. BMO Capital Markets reiterated an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, October 13th. Finally, Wedbush increased their target price on Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.64.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC increased its holdings in Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the period. Salomon & Ludwin LLC purchased a new position in shares of Protagonist Therapeutics during the third quarter valued at approximately $29,000. FNY Investment Advisers LLC bought a new position in shares of Protagonist Therapeutics during the second quarter valued at approximately $27,000. Bessemer Group Inc. raised its holdings in shares of Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after acquiring an additional 318 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in Protagonist Therapeutics by 138.9% in the third quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares during the period. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.